100 related articles for article (PubMed ID: 2153434)
1. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast.
Maloisel F; Dufour P; Bergerat JP; Herbrecht R; Duclos B; Boilletot A; Giron C; Jaeck D; Haennel P; Jung G
Cancer; 1990 Feb; 65(4):851-5. PubMed ID: 2153434
[TBL] [Abstract][Full Text] [Related]
2. Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer.
Ziegler LD; Connelly JH; Frye D; Smith TL; Hortobagyi GN
Cancer; 1991 Aug; 68(3):628-33. PubMed ID: 1648436
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
Koh EH; Buzdar AU; Ames FC; Singletary SE; McNeese MD; Frye D; Holmes FA; Fraschini G; Hug V; Theriault RL
Cancer Chemother Pharmacol; 1990; 27(2):94-100. PubMed ID: 2249339
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
5. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
[TBL] [Abstract][Full Text] [Related]
6. Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
Ang PT; Buzdar AU; Smith TL; Kau S; Hortobagyi GN
J Clin Oncol; 1989 Nov; 7(11):1677-84. PubMed ID: 2809682
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
8. Management of inflammatory carcinoma of the breast. A combined modality approach.
Fastenberg NA; Martin RG; Buzdar AU; Hortobagyi GN; Montague ED; Blumenschein GR; Jessup JM
Am J Clin Oncol; 1985 Apr; 8(2):134-41. PubMed ID: 3841746
[TBL] [Abstract][Full Text] [Related]
9. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Primary chemotherapy and radiosurgical breast-conserving treatment for patients with locally advanced operable breast cancers.
Calais G; Descamps P; Chapet S; Turgeon V; Reynaud-Bougnoux A; Lemarié E; Fignon A; Body G; Bougnoux P; Lansac J
Int J Radiat Oncol Biol Phys; 1993 Apr; 26(1):37-42. PubMed ID: 8387066
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes.
Jaiyesimi IA; Buzdar AU
Am J Clin Oncol; 1992 Apr; 15(2):180-3. PubMed ID: 1313203
[No Abstract] [Full Text] [Related]
14. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Zhang F; Yang Y; Smith T; Kau SW; McConathy JM; Esteva FJ; Kuerer HM; Symmans WF; Buzdar AU; Hortobagyi GN; Pusztai L
Cancer; 2003 Apr; 97(7):1758-65. PubMed ID: 12655533
[TBL] [Abstract][Full Text] [Related]
15. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
Hortobagyi GN; Buzdar AU; Theriault RL; Valero V; Frye D; Booser DJ; Holmes FA; Giralt S; Khouri I; Andersson B; Gajewski JL; Rondon G; Smith TL; Singletary SE; Ames FC; Sneige N; Strom EA; McNeese MD; Deisseroth AB; Champlin RE
J Natl Cancer Inst; 2000 Feb; 92(3):225-33. PubMed ID: 10655439
[TBL] [Abstract][Full Text] [Related]
17. Hormonal therapy in the treatment of mandibular metastasis of breast carcinoma. Report of a case.
Ehlinger P; Peeters LC; Servais J; Fossion E
Int J Oral Maxillofac Surg; 1993 Apr; 22(2):108-9. PubMed ID: 8391556
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
19. The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
Morris DM; Elias EG; Didolkar MS; Brown SD
J Surg Oncol; 1985 Jul; 29(3):154-7. PubMed ID: 3001423
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
